Merck buys Calporta for $576 mln

Merck has acquired Calporta Therapeutics, a portfolio company of COI Pharmaceuticals, which is backed by Avalon Ventures. The purchase price was $576 million. Calporta is developing selective small molecule agonists of TRPML1.

DealsNorth AmericaUSHealthcareBriefs